Bremelanotide Acetate
FDA-approved product (solution, subcutaneous), marketed as Vyleesi (Autoinjector).
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Mental or behavioural disorder
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other gynecologicals
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Bremelanotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- MifepristoneExisting use: Cushing syndrome55.1% AI-predicted activityagainst MRSA50+ registered studies
- SincalideExisting use: Tests for bile duct patency55.1% AI-predicted activityagainst MRSA10 registered studies
- BrigatinibExisting use: Neoplasm, Non-small cell lung carcinoma55.1% AI-predicted activityagainst MRSA48 registered studies
- Ziprasidone MesylateExisting use: Agitation, Bipolar disorder, Bipolar I disorder and 5 more55.0% AI-predicted activityagainst MRSA50+ registered studies
- Nalbuphine HydrochlorideExisting use: Pain55.0% AI-predicted activityagainst MRSA50+ registered studies
- Osimertinib MesylateExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma55.0% AI-predicted activityagainst MRSA26 registered studies
- SpironolactoneExisting use: Ascites, Cardiovascular disease, Cirrhosis of liver and 10 more55.0% AI-predicted activityagainst MRSA50+ registered studies
- Fosdenopterin HydrobromideExisting use: Inborn metal metabolism disorder, Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A54.9% AI-predicted activityagainst MRSANo documented evidence found
- MeprednisoneExisting use: Glucocorticoids54.9% AI-predicted activityagainst MRSA2 registered studies
- Ruxolitinib PhosphateExisting use: Alopecia areata, Cancer, Eczematoid dermatitis and 7 more54.9% AI-predicted activityagainst MRSA50+ registered studies
- EntrectinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma54.8% AI-predicted activityagainst MRSA46 registered studies
- RisdiplamExisting use: Atrophy, Proximal spinal muscular atrophy, Spinal muscular atrophy54.8% AI-predicted activityagainst MRSA33 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
NCT05709444 · start 2022-12-26
Registered record
- Registry ID
- NCT05709444
- Conditions
- Kidney Disease
- Interventions
- Bremelanotide; RAAS inhibition therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2022-12-26
- Completion
- 2024-04-26
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney DiseaseInterventionBremelanotide; RAAS inhibition therapyPhasePhase 2Registry statusCompleted